CR9989A - Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero - Google Patents

Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero

Info

Publication number
CR9989A
CR9989A CR9989A CR9989A CR9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A
Authority
CR
Costa Rica
Prior art keywords
medicinal
polymer
pharmaceutical composition
methods
against cancer
Prior art date
Application number
CR9989A
Other languages
English (en)
Inventor
Singh Amarjit
Singh Sarbjit
K Gupta Ajay
M Kulkarni Mangesh
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR9989A publication Critical patent/CR9989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones mejoradas de drogas contra el cáncer, preferiblemente taxanos, tal como paclitaxel y docetaxel, sus derivados o sus análogos, métodos de fabricación de estas composiciones y métodos de fraccionamiento de las partículas en rango de tamaño particular y métodos para tratar pacientes con cáncer con estas composiciones, que proveen una reducción de los efectos secundarios inducidos por la quimioterapia especialmente una reducción de la alopecia inducida por la quimioterapia. La composición es tal que sustancialmente no hay droga libre en dicha composición.
CR9989A 2005-10-21 2008-05-20 Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero CR9989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10

Publications (1)

Publication Number Publication Date
CR9989A true CR9989A (es) 2008-07-18

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9989A CR9989A (es) 2005-10-21 2008-05-20 Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero

Country Status (13)

Country Link
US (1) US20100166872A1 (es)
EP (1) EP1962906A4 (es)
JP (1) JP2009512682A (es)
AR (1) AR058130A1 (es)
AU (1) AU2006324872B2 (es)
BR (1) BRPI0617663A2 (es)
CA (1) CA2626016A1 (es)
CR (1) CR9989A (es)
EA (1) EA015781B1 (es)
IL (1) IL190882A0 (es)
MA (1) MA29946B1 (es)
RS (1) RS20080167A (es)
WO (1) WO2007069272A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710525C (en) * 2007-12-24 2017-08-22 Sun Pharma Advanced Research Company Limited Nanodispersion
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
EP2252266A1 (en) 2008-02-11 2010-11-24 Yissum Research Development Company of the Hebrew University of Jerusalem Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
WO2009101612A2 (en) 2008-02-11 2009-08-20 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
GB0818747D0 (en) 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
KR20120050414A (ko) 2009-06-19 2012-05-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 약물의 나노분산액 및 그의 제조 방법
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
AU2010296180B2 (en) * 2009-09-21 2016-05-05 Bio-Synectics, Inc Oxaliplatin nanoparticles and method for preparing same
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
CA2819240C (en) * 2010-12-02 2021-06-15 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
KR20140022904A (ko) 2011-04-20 2014-02-25 유니버시티 오브 시드니 치료방법 및 그에 사용가능한 제제
JP6080312B2 (ja) 2011-04-28 2017-02-15 プラットフォーム ブライトワークス トゥー， リミテッド 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
ES2640648T3 (es) 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
NZ734201A (en) 2015-02-01 2024-03-22 Syros Pharmaceuticals Inc High surface-area lyophilized compositions comprising arsenic for oral administration in patients
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
EP3615011A4 (en) * 2017-04-24 2021-01-06 ZY Therapeutics Inc. PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
BR112020016701A2 (pt) 2018-03-28 2020-12-15 Greenmark Biomedical Inc. Métodos para fabricar nanopartículas, para tratar dentes e para fabricar uma nanopartícula de biopolímero, nanopartículas, uso das nanopartículas, nanopartícula de amido reticulada com polifosfato, e, uso de uma nanopartícula de amido reticulada com polifosfato.
MX2021001276A (es) 2018-07-31 2021-07-15 Microbion Corp Composiciones de bismuto-tiol y metodos para tratar heridas.
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
AU784416B2 (en) * 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1246608A4 (en) * 2000-01-05 2005-05-18 Imarx Therapeutics Inc PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc LIPOSOMAL PREPARATIONS OF PHARMACEUTICAL AGENTS STABILIZED BY PROTEINS
KR20110079741A (ko) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Also Published As

Publication number Publication date
BRPI0617663A2 (pt) 2011-08-02
WO2007069272A2 (en) 2007-06-21
AR058130A1 (es) 2008-01-23
EP1962906A2 (en) 2008-09-03
CA2626016A1 (en) 2007-06-21
IL190882A0 (en) 2008-11-03
AU2006324872B2 (en) 2012-03-08
US20100166872A1 (en) 2010-07-01
JP2009512682A (ja) 2009-03-26
RS20080167A (en) 2009-07-15
EA015781B1 (ru) 2011-12-30
AU2006324872A1 (en) 2007-06-21
WO2007069272A3 (en) 2007-08-23
EA200801132A1 (ru) 2009-02-27
MA29946B1 (fr) 2008-11-03
EP1962906A4 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
BRPI0711256A2 (pt) composições anticancerìgenas e método de tratamento de cáncer
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112012023407A2 (pt) composição em pó farmacêutica para instalação, e, processo para a preparação da mesma.
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
CO6640318A2 (es) Formas de dosificación oral de bendamustina
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
AR062960A1 (es) Producto farmaceutico que comprende una composicion farmaceutica que incluye satraplatino para el tratamiento del cancer de prostata metastasico refractario a hormonas y usos del mismo
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas